文献速递临床试验与 GCP流行病学与生物统计

AZD1222新冠疫苗的3期安全性与有效性

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
PubMed 文献 · N Engl J Med · 2021-09-29

这项正在进行的双盲随机安慰剂对照3期试验在美国、智利和秘鲁成人中评估两剂AZD1222预防症状性和重症COVID-19的安全性、疫苗有效性和免疫原性。共32,451名参与者按2:1随机接受AZD1222或安慰剂,总体疫苗有效性为74.0%,65岁及以上为83.5%,安全性良好。

要点

  • AZD1222总体疫苗有效性74.0%,65岁及以上人群为83.5%。
  • 全程接种后AZD1222组无重症或危重症症状性COVID-19病例。
  • 安全性良好,严重不良事件和特别关注不良事件发生率与安慰剂组相似。

核心结论

  • AZD1222在包括老年人在内的多样人群中安全且能有效预防症状性和重症COVID-19。

研究设计与样本

  • 正在进行的双盲、随机、安慰剂对照3期临床试验,在美国、智利和秘鲁成人中比较两剂AZD1222与安慰剂。
  • 共32,451名参与者按2:1随机分配,AZD1222组21,635人,安慰剂组10,816人。

主要发现

  • 总体估计疫苗有效性为74.0%(95%CI 65.3至80.5;P<0.001)。
  • 65岁及以上参与者估计疫苗有效性为83.5%(95%CI 54.2至94.1)。
  • 全程接种分析亚组中,AZD1222组17,662名参与者无重症或危重症症状性COVID-19病例,安慰剂组8,550名参与者中观察到8例(<0.1%)。
  • 预防SARS-CoV-2感染(核衣壳抗体血清转化)的估计疫苗有效性为64.3%(95%CI 56.1至71.0;P<0.001)。
  • SARS-CoV-2刺突蛋白结合抗体和中和抗体在第一剂后升高,第二剂后28天进一步升高。

关键数值与推荐

  • 主要分析为第二剂后15天或以上预防症状性和重症COVID-19的疫苗有效性。
  • 安全性显示严重不良事件、需医疗关注的不良事件和特别关注不良事件发生率低,与安慰剂组相似。

临床怎么用

  • AZD1222可用于包括老年人在内的多样人群预防症状性和重症COVID-19。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021. PMID: 34587382. doi:10.1056/NEJMoa2105290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。